PUBLISHER: The Business Research Company | PRODUCT CODE: 1948356
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948356
A transcatheter mitral valve is a minimally invasive device designed to repair or replace a damaged mitral valve without requiring open-heart surgery. It is delivered to the heart via a thin catheter inserted through a vein or artery, improving blood flow and alleviating symptoms associated with mitral valve disease. This approach is particularly beneficial for patients at high risk for traditional surgical procedures.
The primary product types of transcatheter mitral valves include transcatheter mitral valve replacement and transcatheter mitral valve repair. Transcatheter mitral valve replacement involves inserting a new artificial or biological mitral valve into the heart using a catheter, usually through a blood vessel. It is indicated for conditions such as mitral stenosis and mitral regurgitation and is utilized by various end users, including hospitals, ambulatory surgical centers, and cardiac catheterization laboratories.
Tariffs have influenced the transcatheter mitral valve market by increasing costs for imported medical devices and specialized components such as self-expanding and balloon-expandable valves. Segments like transcatheter valve replacement and repair devices are most affected, particularly in regions such as North America and Asia-Pacific where imports constitute a major portion of supply. While tariffs have increased production costs and limited immediate accessibility, they have also encouraged local manufacturing initiatives, domestic innovation, and diversification of supply chains, supporting long-term market growth.
The transcatheter mitral valve market research report is one of a series of new reports from The Business Research Company that provides transcatheter mitral valve market statistics, including transcatheter mitral valve industry global market size, regional shares, competitors with a transcatheter mitral valve market share, detailed transcatheter mitral valve market segments, market trends and opportunities, and any further data you may need to thrive in the transcatheter mitral valve industry. This transcatheter mitral valve market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The transcatheter mitral valve market size has grown strongly in recent years. It will grow from $1.61 billion in 2025 to $1.76 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to limited availability of transcatheter mitral valves, reliance on surgical valve replacement, growing awareness of mitral valve disease, increasing hospital cardiac procedures, early adoption in high-risk patient groups.
The transcatheter mitral valve market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to technological advancement in transcatheter valve designs, rising geriatric population with mitral valve disorders, expansion of cardiac catheterization laboratories, increasing healthcare expenditure, adoption of minimally invasive cardiac intervention programs. Major trends in the forecast period include rising adoption of minimally invasive cardiac procedures, increasing use of self-expanding and balloon-expandable valves, expansion of edge-to-edge and chordal repair devices, growing prevalence of mitral valve diseases among elderly patients, integration of imaging and navigation systems for procedure accuracy.
The rising prevalence of heart diseases is expected to drive the growth of the transcatheter mitral valve market in the coming years. Heart diseases are conditions that impair the structure or function of the heart, reducing its efficiency in pumping blood. This increase is largely driven by aging populations, as age-related deterioration of the heart and blood vessels heightens the risk of conditions such as mitral valve regurgitation, heart failure, and arrhythmias. Transcatheter mitral valves help manage heart disease by repairing or replacing a damaged mitral valve, restoring proper blood flow between the heart's chambers, improving cardiac function, and alleviating symptoms. For example, in December 2024, the National Center for Health Statistics, a US-based government agency, reported that the age-adjusted death rate in 2023 fell to 750.5 per 100,000 standard population, a 6.0% decrease from 798.8 in 2022. Therefore, the increasing prevalence of heart diseases is driving growth in the transcatheter mitral valve market.
Key players in the transcatheter mitral valve market are concentrating on developing advanced devices, such as transcatheter mitral valve replacement (TMVR) systems, to broaden treatment options for high-risk or inoperable patients. TMVR systems are minimally invasive devices that replace a damaged or diseased mitral valve with an artificial valve via a catheter-based approach, eliminating the need for open-heart surgery. For instance, in May 2025, Abbott Laboratories, a US-based medical device company, launched Tendyne, which received FDA approval. This self-expanding, nitinol-framed valve is available in multiple sizes to suit different anatomies and can be fully repositioned or retrieved during implantation. Delivered through a small chest incision, the system allows for a minimally invasive procedure typically completed in around 1.5 hours. Designed for quicker recovery, most patients can be discharged within three days, providing a transformative option for high-risk mitral valve patients without viable surgical alternatives.
In April 2024, TechWald Holding S.p.A., an Italy-based medical technology investment company, acquired Valcare Medical Inc. for an undisclosed sum. This acquisition aims to strengthen TechWald Holding's presence in the structural heart device market, focusing on transcatheter mitral valve repair and replacement. The deal enhances its cardiovascular portfolio, accelerates Valcare's device development and commercialization, and bolsters its position in minimally invasive heart valve therapies. Valcare Medical Inc., based in Israel, specializes in minimally invasive transcatheter treatments for mitral regurgitation.
Major companies operating in the transcatheter mitral valve market are Abbott Laboratories, Medtronic Inc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Meril Life Sciences Private Limited, MicroPort Scientific Corporation, Venus Medtech Inc., Cardiac Dimensions Inc., JenaValve Technology Inc., Ancora Heart Inc, Peijia Medical Limited, Micro Interventional Devices Inc., 4C Medical Technologies Inc., NeoChord Inc., Xeltis AG, Valcare Medical Inc., Colibri Heart Valve LLC, MitrAssist Ltd., HighLife SAS, Navigate Cardiac Structures Inc., Cardiovalve Ltd.
North America was the largest region in the transcatheter mitral valve market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transcatheter mitral valve market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the transcatheter mitral valve market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transcatheter mitral valve market consists of sales of transcatheter annuloplasty devices, guiding catheters, chordal repair devices, and adjunctive imaging and navigation systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transcatheter Mitral Valve Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses transcatheter mitral valve market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for transcatheter mitral valve ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transcatheter mitral valve market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.